ArticleCognitive and behavioral practice2026
An Open-Phase Pilot Trial of an Integration of Prolonged Exposure Therapy and the Coping Long-Term With Active Suicide Program.
Article in Cognitive and behavioral practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Posttraumatic stress disorder (PTSD) is associated with an increased risk for suicidal ideation and behavior, yet clinical practice guidelines for addressing suicide risk in the context of PTSD are not yet available. This open trial evaluated the safety and preliminary efficacy of an integration of a trauma-focused treatment, prolonged exposure therapy (PE), with the coping long-term with an active suicide program (CLASP). CLASP-PE was delivered to patients with PTSD who reported suicidal ideation with intent, a plan, or a past-month attempt. Veterans or active-duty military personnel with a confirmed PTSD diagnosis and suicide risk (N = 14; 86% male) began the CLASP-PE protocol, which was delivered via telemedicine in 10-16 sessions, including a session with a support person as feasible. Two participants only provided baseline data; of the remaining 12, 8 participants (n = 66.7%) completed their treatment sessions. Participants reported significant reductions in PTSD symptoms (p < .05), suicidal ideation (p < .05), and depression symptoms (p < .001). The degree of reduction in PTSD symptoms and depression symptoms in treatment predicted the degree of reduction in suicidal ideation in treatment. No suicide attempts or serious adverse events occurred in treatment. A case vignette is shared. CLASP-PE was safe, with preliminary evidence supporting its efficacy. Additional randomized controlled trial research is needed to evaluate its impact compared to a control group. If replicated, the CLASP-PE protocol would be a useful and safe clinical tool for individuals with PTSD who are experiencing significant suicide risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.